相关实验视频

Updated: Jun 2, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

高密度脂蛋白生物仿真无机有机复合纳米系统用于动脉样硬化治疗

Yunpeng Zhang^1,2,3, Danni Liu^1,2,3, Yaoqi Wang^1,2,3

¹School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.

|March 13, 2025

概括

这项研究开发了一种用于动脉样硬化治疗的新型抗氧化纳米粒子系统. ApoA1-修饰的纳米复合物向斑块,减少氧化应激和清除胆固醇,以进行有效的治疗.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
心血管研究研究心血管研究

背景情况:

动脉样硬化 (AS) 是心血管疾病的主要原因,其特点是氧化应激.
抗氧化剂治疗是管理AS的一个关键策略.
开发有针对性的药物输送系统对于有效的AS治疗至关重要.

研究的目的:

为AS治疗设计和建造一个阿波利波蛋白A1 (ApoA1) 修饰的无机有机复合纳米系统.
为了创建一个高密度脂蛋白模仿纳米复合物,以有针对性地传递到AS斑块.
为了利用抗氧化活性和胆固醇排放的双重治疗功能.

主要方法:

ApoA1对碳氧化二氧化/四氧化 (CeO2/Mn3O4) 纳米粒子的共价结合.
构建一种具有高密度脂蛋白样结构的无机有机纳米复合体.
利用ApoA1的巨细胞识别来针对性地传递到AS病变.

主要成果:

纳米复合物有效地将抗氧化纳米颗粒传递给AS斑块.
CeO2/Mn3O4显示出强大的抗氧化作用,减轻了损伤部位的氧化应激.
ApoA1促进了胆固醇排放,有助于消除脂质斑块.

结论:

经过ApoA1修饰的CeO2/Mn3O4纳米复合体显示出对动脉样硬化有显著的治疗潜力.
这种新的系统通过对抗氧化应激和促进胆固醇的去除,提供了一种双重作用的方法.
通过ApoA1识别进行有针对性的治疗,可以提高AS治疗的疗效.

关键词:

在 ApoA1A1 中.抗氧化剂是一种抗氧化剂.动脉样硬化动脉样硬化 - 混合化纳米粒子.

更多相关视频

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

相关概念视频

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...